For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
Medical Research

Eczema Patients at 30% Higher Risk of Suicidal Thoughts

New study reveals atopic eczema patients face increased risk of suicidal ideation, identifying key factors driving this elevated risk for better patient care.

April 5, 2026
3 min read
Drug Update

Executive Brief

  • The News: 13.2% of adults with atopic eczema report suicidal ideation.
  • Clinical Win: Moderate-to-severe AE doubles suicidal ideation odds (OR=2.01).
  • Target Specialty: Dermatologists treating adults with atopic eczema.

Key Data at a Glance

Condition: Atopic eczema (AE)

Prevalence: Over 200 million people worldwide

Suicidal Ideation Rate in AE: 13.2%

Suicidal Ideation Rate in Controls: 8.5%

Sample Size (N=): 30,801 adults

Key Risk Factor: Moderate-to-severe AE (OR=2.01)

Eczema Patients at 30% Higher Risk of Suicidal Thoughts

A new international study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that adults with atopic eczema (AE) are significantly more likely to experience suicidal thoughts, with researchers uncovering the key factors driving this elevated risk.

As one of the largest global investigations to examine the link between AE and suicidal ideation, the "Scars of Life" study surveyed 30,801 adults across 27 countries in 2024. Among them, 15,223 were adults with physician-confirmed current AE, while 7,968 adults without AE served as controls.

Participants with current AE were grouped by age of AE onset—childhood, adolescence, or adulthood—and completed a detailed online questionnaire capturing sociodemographic information, self-reported suicidal ideation, severity of itch and skin pain, AE severity, and experiences of skin-related stigmatization.

The results showed that 13.2% of adults with AE reported suicidal ideation, compared with 8.5% of adults without AE. All AE subgroups—whether the condition began in childhood, adolescence, or adulthood—had higher odds of suicidal ideation than controls, highlighting the widespread mental health burden of the condition.

Atopic eczema, a chronic inflammatory skin condition affecting more than 200 million people worldwide, is characterized by recurring episodes of dry, itchy and inflamed skin. Beyond the physical symptoms, its impact on mental health is increasingly recognized, with many experiencing anxiety, depression, and social stigma, alongside the daily challenges of managing their condition.

Importantly, the study identified several factors strongly associated with suicidal ideation in adults with AE. Younger adults, particularly those under 30, were more likely to report suicidal thoughts (OR=1.6), as were individuals with obesity (OR=1.29).

Clinical features also played a major role: moderate-to-severe AE doubled the odds of suicidal ideation (OR=2.01), while pruritus (itching), skin pain, and high overall symptom intensity were all significantly associated with increased risk.

Psychosocial and sleep factors further contributed to risk. Adults with suicidal thoughts reported higher levels of stigmatization and more prevalent sleep disorders, with mixed insomnia—difficulty falling and staying asleep—notably linked to suicidal ideation (OR=1.78).

Dr. Delphine Kerob, one of the lead researchers, commented, "These findings reveal a critical insight from our large-scale study, which seeks to uncover the hidden, long-term impact of living with common inflammatory skin conditions such as atopic eczema."

"The results highlight that the effects of atopic eczema are more than skin deep, with suicidal thoughts representing a serious and frequent concern that is often overlooked by health care professionals," she continued.

"By identifying the main risk factors behind suicidal ideation in this population, we hope this study will help health care professionals better recognize and address these challenges, supporting patients' overall well-being more effectively."

Discussing the next steps for research, Dr. Kerob said, "Looking ahead, we are investigating why suicidal ideation occurs at different rates across countries, which may reflect important cultural differences. At the same time, ongoing analyses from the 'Scars of Life' study are enhancing our understanding of what happens beneath the surface in patients with atopic eczema."

Provided by European Academy of Dermatology and Venereology

Clinical Perspective — Dr. Amit Desai, Endocrinology

Workflow: I'm now more vigilant about screening for suicidal ideation in my patients with atopic eczema, given the study's finding that 13.2% of adults with AE reported suicidal ideation. This means I'll be asking more targeted questions about mental health and skin-related stigmatization during routine check-ups. As a result, I'll also be considering referrals to mental health professionals for those with moderate-to-severe AE.

Economics: The article doesn't address cost directly, but I'd expect the economic burden of AE to increase with the added mental health component. Managing AE already requires significant resources, and the potential need for additional psychiatric care or therapy will likely add to this burden. As we consider treatment plans, we'll need to factor in the potential costs of addressing suicidal ideation and other mental health concerns.

Patient Outcomes: The study's finding that moderate-to-severe AE doubles the odds of suicidal ideation (OR=2.01) is particularly concerning. I'll be working closely with my patients to develop strategies for managing their symptoms and reducing their risk of suicidal thoughts. For example, addressing sleep disorders like mixed insomnia, which is notably linked to suicidal ideation (OR=1.78), will be a key part of our treatment plans.

Transparency & Corrections

HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].

Drug Update Briefing

Get weekly drug updates for Medical Research in your inbox.

Related Drug Updates